Fate Therapeutics Inc (FATE)

[jondoeuk]

First patient has been enrolled in the FT538 trial. Multiple cycles each comprising Cy/Flu conditioning, three doses of FT538, and mAb therapy. Two 2 cycles; potential to administer additional cycles with clinical benefit and upon relapse. The dose ranges from 100M to 1.5B cells and each mAb combination enrolls independently. For anti-PD-1 and anti-PD-L1 it will be NSCLC, GE, HNSCC, TNBC and UC. With anti-HER2, gastric and breast, and anti-EGFR, it is NSCLC, CRC and HNSCC.